Today: 8 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Bitcoin meets gold: 21Shares’ BOLD ETP lands on the London Stock Exchange

Bitcoin meets gold: 21Shares’ BOLD ETP lands on the London Stock Exchange

21Shares listed its Bitcoin Gold ETP, BOLD, on the London Stock Exchange, combining bitcoin and physical gold in a single security. The launch follows the UK’s lifting of its ban on certain crypto exchange-traded notes for retail investors. BOLD carries a 0.65% annual fee and had $40.1 million under management as of January 12. The product’s allocation shifts monthly based on asset volatility.
14 January 2026
···
Concentrix stock jumps as CNXC sets 2026 cash-flow target after $1.5 billion goodwill write-down

Concentrix stock jumps as CNXC sets 2026 cash-flow target after $1.5 billion goodwill write-down

Concentrix shares rose 3.9% to $40.71 Wednesday after the company posted Q4 revenue of $2.55 billion and a $1.52 billion goodwill impairment charge. Adjusted profit and cash flow held steady, but BofA and Baird cut price targets, citing margin pressure. Concentrix forecast 2026 revenue of up to $10.18 billion and non-GAAP EPS as high as $12.07.
14 January 2026
··
Coney Island finally gets its own BID — and a July 2026 launch is now on the clock

Coney Island finally gets its own BID — and a July 2026 launch is now on the clock

Coney Island’s business improvement district will launch July 1, 2026, after supporters confirmed city approval. The BID will cover Mermaid and Surf avenues, aiming to fund sanitation, safety, and promotions through property owner assessments. The district includes over 350 businesses and about 50,000 residents. Boundaries stretch from the New York Aquarium to West 33rd Street.
14 January 2026
Bitcoin breaks $96,000 as U.S. crypto regulation bill and softer inflation data lift prices

Bitcoin breaks $96,000 as U.S. crypto regulation bill and softer inflation data lift prices

Bitcoin rose 3.6% to nearly $96,876 as ether and XRP also advanced ahead of a Senate Banking Committee debate on crypto regulation. U.S. senators introduced a draft bill that would clarify oversight of digital assets and restrict stablecoin interest payouts. December CPI data showed core inflation up 0.2% for the month. The Federal Reserve is expected to pause rate hikes at its next meeting.
14 January 2026
··
UEC stock jumps nearly 11% as uranium supply squeeze talk returns — and a Feb. 27 vote looms

UEC stock jumps nearly 11% as uranium supply squeeze talk returns — and a Feb. 27 vote looms

Uranium Energy Corp shares jumped 10.8% to $17.23 Wednesday, outpacing sector gains as traders responded to tightening U.S. uranium supply. Anfield Energy disclosed a $4 million subscription receipt purchase by a Uranium Energy unit, pending shareholder approval by Feb. 27. U.S. uranium mine output is projected at 1 million pounds this year, far below annual consumption of over 50 million pounds, according to Reuters.
14 January 2026
·
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Infosys stock jumps nearly 9% after INFY lifts FY26 outlook — what investors watch next

Infosys stock jumps nearly 9% after INFY lifts FY26 outlook — what investors watch next

Infosys’ U.S. shares jumped 8.9% to $19.08 after the company raised its fiscal 2026 revenue growth outlook to 3.0%-3.5% and reported $5.099 billion in quarterly revenue. Net profit in India fell 2.2% due to a one-time charge. Large deal wins totaled $4.8 billion. Bank of America raised its price target to $20.50, citing stronger growth in key sectors.
14 January 2026
··
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
14 January 2026
··
CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure shares rose about 8% Wednesday after the company announced a $900 million private placement of senior secured notes due 2033 with a 5.625% coupon and a $1.2 billion term loan. The company also confirmed its acquisition of Husky Technologies and will rebrand, trading as “GPGI” from Jan. 23. The Husky deal included $688.7 million in cash and nearly 55 million Class A shares.
14 January 2026
·
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences shares climbed about 8% Wednesday after the company set a 2026 timetable for U.S. filings of its lead drug, bezuclastinib. Cogent expects FDA acceptance of its first application by the end of February and aims for a possible commercial launch in the second half of 2026. The stock traded at $38.17 midday. The company began the year with about $900 million in cash.
14 January 2026
·
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics shares rose 10.6% to $27.59 by midday Wednesday after the company set timelines for key clinical trial readouts in muscle and heart diseases. Top-line data for Becker muscular dystrophy is expected in Q4 2026, with a U.S. drug application planned for early 2027. Investors are watching for Phase 2 and Phase 1 heart program results in the first half of 2026. Trading volume reached about 1 million shares.
14 January 2026
··
CBA shares slide again — here’s what’s spooking Commonwealth Bank investors ahead of earnings

CBA shares slide again — here’s what’s spooking Commonwealth Bank investors ahead of earnings

Commonwealth Bank of Australia shares fell 1.3% to A$152.88 Wednesday, lagging the ASX 200’s 0.14% gain. Morgan Stanley flagged CBA’s 45% valuation premium as a risk for 2026 returns. CBA wage data showed a 0.8% quarterly rise and steady 4.3% unemployment. The Reserve Bank of Australia will announce its next policy decision on Feb. 3.
14 January 2026
··
1 … 178 179 180 181 182 … 535

Stock Market Today

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

8 February 2026
New York, Feb 7, 2026, 17:35 EST — Market closed. Abbott Laboratories (ABT) shares rose 1.6% to $110.83 on Friday, extending a second straight day of gains. It trailed a broader rally in which the S&P 500 climbed 1.97% and the Dow gained 2.47%, and it remains 21.53% below its 52-week high of $141.23, with 9.9 million shares changing hands versus a 50-day average of 8.9 million. (MarketWatch) U.S. markets are shut on Saturday, leaving investors a weekend to focus on regulation rather than price action. The Food and Drug Administration updated a Class I recall notice — its most
Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

8 February 2026
Verizon shares fell 1.7% to $46.31 on Friday, ending a seven-day rally and lagging a broad market rebound. The drop follows a leadership shakeup in the consumer unit, with Sowmyanarayan Sampath stepping down and Alfonso Villanueva named interim chief. Investors await delayed U.S. jobs and inflation data next week, which could affect rate-sensitive stocks.
Go toTop